EyePoint Inc (EYPT)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$15.28
Buy
$16.60
$-0.11 (-0.68%)
Prices updated at 12 Dec 2025, 21:10 EST
| Prices minimum 15 mins delay
Prices in USD
EyePoint Pharmaceuticals Inc, formerly pSivida Corp develops tiny, sustained-release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2023 | 2024 |
|---|---|---|
| 46m | 43m | |
| 41m | 40m | |
| -75m | -146m | |
| -163.13 | -337.06 | |
| -71m | -131m | |
| -69m | -129m | |
| Sales, General and administrative | 52m | 52m |
| Interest expenses | 1m | 14,000 |
| Provision for income taxes | 83,000 | 90,000 |
| Operating expenses | 116m | 185m |
| Income before taxes | -71m | -131m |
| Net income available to common shareholders | -71m | -131m |
| -1.82 | -2.32 | |
| Net interest income | 6m | 15m |
| Advertising and promotion | - | - |
| Net investment income, net | - | - |
| Realised capital gains (losses), net | - | - |
| Total benefits, claims and expenses | - | - |
| Earnings per share (diluted) | -1.82 | -2.32 |
| Free cash flow per share | 0.2444 | -2.3284 |
| Book value/share | 1.1953 | 3.2041 |
| Debt equity ratio | 0.018421 | 0.064957 |
Balance sheet
Year | 2023 | 2024 |
|---|---|---|
| Current assets | 345m | 383m |
| Current liabilities | 63m | 49m |
| Total capital | 266m | 337m |
| Total debt | 5m | 22m |
| Total equity | 266m | 337m |
| Total non current liabilities | - | - |
| Loans | - | - |
| Total assets | 355m | 418m |
| Total liabilities | - | - |
| Cash and cash equivalents | 281m | 100m |
| Common stock | 49m | 68m |
Cash flow
Year | 2023 | 2024 |
|---|---|---|
| Cash at beginning of period | 96m | 281m |
| Cash dividends paid | - | - |
| -2m | -130m | |
| Investments (gains) losses | -3m | -219m |
| 281m | 100m | |
| Net income | - | - |
| 2m | -126m | |
| -3m | -4m |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.
